MRK Merck KGaA

163.01USD148.30 EUR · XETRA-0.07%Mkt Cap: 70.92B USDP/E: 33.57

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic…

Institutional holders14 on file

Key Statistics

Company
Market Cap70.92B USD
Enterprise Value79.20B USD
Revenue (TTM)23.57B USD
Gross Profit13.57B USD
Net Income (TTM)2.87B USD
Revenue/Share54.25 USD
Last Price163.01 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees61.9K
CountryDE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINDE0006599905
Valuation
P/E (Trailing)33.57
P/E (Forward)16.28
PEG2.41
EV/EBITDA11.90
EV/Revenue3.36
P/S3.01
P/B2.05
EPS (TTM)4.86 USD
EPS (Forward)10.02 USD
52W Range
110.6986% of range171.75
52W High171.75 USD
52W Low110.69 USD
Profitability
Gross Margin58.51%
Oper. Margin17.04%
EBITDA Margin28.24%
Profit Margin12.36%
ROE9.12%
ROA5.06%
ROIC7.67%
ROCE8.61%
Growth
Revenue Growth5.80%
Earnings Growth-49.80%
Cash Flow & Leverage
Operating CF4.32B USD
CapEx (TTM)2.15B USD
FCF Margin10.40%
FCF Yield3.46%
Net Debt8.49B USD
Net Debt/EBITDA1.27
Net Debt/FCF3.46
Balance Sheet
Debt/Equity0.42
Current Ratio1.69
Quick Ratio1.02
Book Value/Sh79.61 USD
Cash/Share10.85 USD
Dividends
Fwd Div Rate2.42 USD
Trail. Div Rate0.00 USD
Div. Yield1.46%
5Y Avg Yield1.31%
Payout Ratio49.77%
Ex-Div DateApr 27, 2026
Pay Date—
Splits
Last Split2:1
Split DateJun 30, 2014
Analyst Consensus
Rating2.2 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)175.09 USD
Upside (mean)+7.4%
Target Range148.39 USD – 197.86 USD
148.39+7.4% to mean197.86
# Analysts14
Ownership
Shares Out.129.24M
Float128.58M
Insiders0.00%
Institutions60.75%
Technical
SMA 50155.42 (+4.9%)
SMA 200143.76 (+13.4%)
Beta0.81
S&P 52W Chg12.00%
Avg Vol (30d)283.70K
Avg Vol (10d)321.59K
Technical Indicators
RSI (14)53.8
MACD2.0054
MACD Signal2.4726
MACD Hist.-0.4672
BB Upper168.81 USD
BB Middle163.45 USD
BB Lower158.09 USD
BB Width6.56%
ATR (14)3.632 USD
Vol Ratio (20d)0.81x

About Merck (ETR: MRK)

›

Merck (ETR: MRK) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 61,949 employees.

The shares were at 148.30 EUR on 19 November 2026, up 28.2% over 52 weeks. Its 52-week range is 100.70 EUR to 156.25 EUR: the price is 5.1% below the high and 47.3% above the low.

At a market capitalisation of 64.52B EUR, it trades at 33.6 times trailing earnings and 16.3 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 36% for MRK. It pays a dividend yielding 1.46% (it pays out 50% of its earnings), against a median of 2.01% among the dividend payers in that peer group.

Merck reports return on equity of 9.1%, an operating margin of 17.0% and revenue up 5.8% year over year.

Its debt exceeds its cash by 7.72B EUR, a debt-to-equity ratio of 0.42. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 159.29 EUR is 7.4% above the current price. The next earnings report is expected on 4 March 2027.